Bone Marrow Transplantation News

In this episode, Julie Rubinstein, MBA, discusses her journey into the cancer space, the importance of personalized medicine and how her father’s cancer diagnosis played a role in her career.

The FDA granted priority review to maribavir for the treatment of patients with transplant-associated cytomegalovirus infection that was resistant or refractory to prior treatment, according to the agent’s manufacturer.

BK virus-specific cytotoxic T lymphocytes from healthy donors appeared safe and effective for patients with BK virus-associated hemorrhagic cystitis after undergoing allogeneic hematopoietic stem cell transplantation.

The addition of motixafortide to standard treatment improved hematopoietic stem cell target mobilization for autologous bone marrow transplantation among patients with multiple myeloma, according to the agent’s manufacturer.

Marcos J. de Lima, MD, has been appointed to key leadership positions at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Patients with mantle cell lymphoma who were unmarried, had less education or had more comorbidities appeared less likely to undergo autologous hematopoietic stem cell transplantation, according to a study published in Blood Advances.

More than 80% of patients who responded to therapy with tabelecleucel for Epstein-Barr virus-driven post-transplant lymphoproliferative disease remained alive 2 years after initial treatment, study results showed.

We have not yet moved away from bone marrow transplant for these patients, and I believe the best outcomes remain with an early transplant.

Although potentially curative for many hematologic malignancies, hematopoietic stem cell transplantation historically has been associated with substantial morbidity and mortality.

The FDA granted fast track designation to neihulizumab for treatment of steroid-refractory acute graft-versus-host disease according to the agent’s manufacturer.